The natural history model of hepatitis C virus infection and the economic evaluation of alpha interferon treatment

Journal of Epidemiology

Volumn 12, Issue 1, 2002, Pages 22-32

  Hayashida, Kenshi ^a   Nagasue, Ichiro ^b   Fukuda, Takashi ^c   Gunji, Atsuaki ^d  

^a KYOTO UNIVERSITY   (Japan)

^b Pfizer Pharmaceutical Inc

^c UNIVERSITY OF TOKYO   (Japan)

^d Seigakuin University   (Japan)

Author keywords

Economic evaluation; Hepatitis C; Interferon therapy; Markov chain model

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; HEPATITIS C; HUMAN; JAPAN; MALE; MIDDLE AGED; MORTALITY; PROBABILITY; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HEPATITIS C; HUMANS; INTERFERON-ALPHA; JAPAN; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036370190     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.12.22     Document Type: Article

References (27)

1. Marcellin P, Boyer N, Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med, 1997; 127: 875-881.
2. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-α 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med, 127: 855-865.
3. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, Gross JB Jr. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med, 1997; 127: 866-874.
4. Moriguchi H, Sato C. The socioeconomic evaluation of strategical treatment for chronic hepatitis C with interferon. Jpn J Health Econ Policy, 1996; 3: 169-178. (in Japanese)
5. Wong JB. Cost-effectiveness of treatments for chronic hepatitis C. Am J Med, 1999; 107(6B): 74S-78S.
6. The Japan Society of Hepatology. Kangan Hakusho. 1999. (in Japanese)
7. Brown JL. Efficacy of combined interferon and ribavirin for treatment of hepatitis C. Lancet, 1998; 351: 78-79.
8. Koff RS. Interferon-α for chronic hepatitis C: reducing the uncertainties. Ann Intern Med, 1997; 127: 918-920.
9. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S, Ogawa N. Clinical study of treatment with interferon α-2b in patients with chronic active hepatitis C. Kiso To Rinsho, 1996; 30: 57-93. (in Japanese)
10. The Liver Cancer Study Group of Japan. Eleventh primary liver cancer in Japan 1990-1991. 1994. (in Japanese)
11. Ikeda K, Saitoh S, Koida I et al. A Multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology, 1993; 18: 47-53.
12. Kato Y, Nakata K, Omagari K et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infections hepatitis viruses. Cancer, 1994; 74: 2234-2238.
13. Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med, 1993; 328: 1797-1801.
14. Takase K, Nakano T, Tameda Y, Kosaka Y. Histological findings of the liver. Nippon Rinsyo, 1995; 53 (Suppl): 662-666. (in Japanese)
15. Yoshizawa H, Tanaka J, Ohhori K et al. Prevalence of the HCV associated markers among blood donors in Japan. Nippon Rinsyo, 1991; 49: 357-365. (in Japanese)
16. Yoshizawa H. Blood transfusion and hepatitis C. In; S Hattori, ed. Hepatitis C medical. Medical View, Tokyo, 1994: 103-107. (in Japanese)
17. Kiyosawa K, Tanaka E, Sodeyama T, Furuta S. Chronic hepatitis C, liver cirrhosis. In; Furuta S, Suzuki H, eds. Hepatitis C update, 1993: 129-139. (in Japanese)
18. Ministry of Health and Welfare. Prescription survey of Japan. 1993. (in Japanese)
19. Ministry of Health and Welfare. Patient survey of Japan. 1990. (in Japanese)
20. Nakamura Y, Hashimoto S, Koike S et al. References about estimates of total number of patients based on patient survey of Ministry of Health and Welfare. Kosei No Shihyo, 1994; 41(5): 3-9. (in Japanese)
21. Hashimoto S, Nakamura Y, Koike S et al. Method of estimates of total number of patients based on patient survey of Ministry of Health and Welfare. Kosei No Shihyo, 1994; 41(6): 3-12. (in Japanese)
22. Koike S, Imamura T, Onodera S et al. Validity of total number of patients based on patient survey of Ministry of Health and Welfare. Kosei No Shihyo, 1994; 41(8): 9-15. (in Japanese)
23. Nakamura Y, Hashimoto S, Koike S et al. Study of application of total number of patients based on patient survey of Ministry of Health and Welfare. Kosei No Shihyo, 1994; 41(10): 26-33. (in Japanese)
24. Ministry of Labor. Wage statistics of Japan. 1995. (in Japanese)
25. Sasaki F, Tanaka J, Moriya T et al. Very Low incidence rates of community-acquired hepatitis C virus infection in company employees, long-term inpatients, and blood donors in Japan. J Epidemiol, 1996; 6: 198-203.
26. Yuki N, Hayashi N, Kasahara A et al. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol, 1995;22:457-463.
27. Yokosuka O, Kato N, Hosoda K et al. Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA. Gut, 1995; 37: 721-726: